FNDC5 Patent for Neurological Disorders Treatment - Dana-Farber
Summary
The European Patent Office published patent application EP3052137A1 filed by Dana-Farber Cancer Institute, Inc. covering compositions and methods for identifying, assessing, preventing, and treating neurological disorders and diseases using FNDC5. The application names Bruce M. Spiegelman and Christiane D. WRANN as inventors and includes International Patent Classifications A61K 38/17 and related therapeutic categories.
What changed
EPO published European patent application EP3052137A1 (A1 publication with search report) for Dana-Farber Cancer Institute covering FNDC5-based compositions and methods for neurological disorder treatment. The application claims therapeutic uses, pharmaceutical compositions, and diagnostic applications relating to the FNDC5 protein. The patent designates all EPC contracting states including DE, FR, GB, IT, NL, ES, and others.
Pharmaceutical companies and biotechnology firms conducting research on FNDC5, irisin, or related neurological therapies should review this application to assess potential freedom-to-operate implications. Healthcare researchers studying exercise-induced neurological benefits should monitor the patent prosecution timeline. The patent has not yet been granted; third parties may file observations or opposition once granted.
What to do next
- Review patent claims for FNDC5-related products and assess freedom-to-operate exposure
- Monitor prosecution status of EP3052137A1 for claim scope and geographic coverage
- Evaluate whether ongoing or planned research activities may be affected by potential exclusive rights
Source document (simplified)
IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES USING FNDC5
Publication EP3052137A1 Kind: A1 Mar 25, 2026
Applicants
Dana-Farber Cancer Institute, Inc.
Inventors
SPIEGELMAN, Bruce M., WRANN, Christiane D.
IPC Classifications
A61K 38/17 20060101AFI20170412BHEP A61K 48/00 20060101ALI20170412BHEP G01N 33/50 20060101ALI20170412BHEP C12Q 1/68 20060101ALI20170412BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.